[HTML][HTML] Enhancing treatment success in inflammatory bowel disease: optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
A Armuzzi, Y Bouhnik, F Cummings, M Bettey… - Digestive and Liver …, 2020 - Elsevier
Anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab have greatly
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
A Armuzzi, Y Bouhnik, F Cummings… - Digestive and Liver …, 2020 - europepmc.org
Anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab have greatly
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
[引用][C] Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
A Armuzzi, Y Bouhnik, F Cummings… - … AND LIVER DISEASE, 2020 - iris.hunimed.eu
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF
agents and utilising their biosimilars in clinical practice IRIS IRIS Home Sfoglia Macrotipologie …
agents and utilising their biosimilars in clinical practice IRIS IRIS Home Sfoglia Macrotipologie …
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
A Armuzzi, Y Bouhnik, F Cummings… - Digestive and liver …, 2020 - pubmed.ncbi.nlm.nih.gov
Anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab have greatly
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
A Armuzzi, Y Bouhnik, F Cummings… - Digestive and Liver …, 2020 - dldjournalonline.com
Anti-tumour necrosis factor (TNF) agents such as infliximab and adalimumab have greatly
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …
altered the treatment landscape in inflammatory bowel disease (IBD). However, there are …